Akari Therapeutics reports Q2 results (AKTX:NASDAQ)
· seekingalpha.com
Akari Therapeutics (AKTX) Q2 results: wider net loss, cash update, and rising R&D spend tied to AKTX-101 IND enabling work.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...